Evkeeza® (evinacumab-dgnb) sbla for children with ultra-rare inherited form of high cholesterol accepted for fda priority review

If approved, evkeeza would be the first and only treatment of its kind to help children as young as 5 years old control dangerously high levels of ldl cholesterol caused by homozygous familial hypercholesterolemia tarrytown, n.y. , nov. 30, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the u.s. food and drug administration (fda) has accepted for priority review the supplemental biologics license application (sbla) for evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (hofh).
REGN Ratings Summary
REGN Quant Ranking